Logo image of VERU

VERU INC (VERU) Stock Fundamental Analysis

NASDAQ:VERU - Nasdaq - US92536C1036 - Common Stock - Currency: USD

0.5417  -0.01 (-1.49%)

Premarket: 0.56 +0.02 (+3.38%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VERU. VERU was compared to 198 industry peers in the Pharmaceuticals industry. VERU has a bad profitability rating. Also its financial health evaluation is rather negative. VERU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VERU had negative earnings in the past year.
VERU had a negative operating cash flow in the past year.
VERU had negative earnings in 4 of the past 5 years.
VERU had a negative operating cash flow in each of the past 5 years.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

VERU's Return On Assets of -62.57% is on the low side compared to the rest of the industry. VERU is outperformed by 67.17% of its industry peers.
With a Return On Equity value of -116.97%, VERU is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

The Gross Margin of VERU (34.66%) is comparable to the rest of the industry.
VERU's Gross Margin has declined in the last couple of years.
VERU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
VERU has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VERU has been increased compared to 5 years ago.
VERU has a better debt/assets ratio than last year.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -6.47, we must say that VERU is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.47, VERU is doing worse than 67.68% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that VERU is not too dependend on debt financing.
VERU's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. VERU outperforms 44.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -6.47
ROIC/WACCN/A
WACC9.54%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

VERU has a Current Ratio of 2.97. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.97, VERU is in line with its industry, outperforming 52.53% of the companies in the same industry.
VERU has a Quick Ratio of 2.62. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.62, VERU is in line with its industry, outperforming 55.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.62
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.90% over the past year.
VERU shows a small growth in Revenue. In the last year, the Revenue has grown by 3.62%.
Measured over the past years, VERU shows a very negative growth in Revenue. The Revenue has been decreasing by -11.89% on average per year.
EPS 1Y (TTM)67.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 1.30% on average over the next years.
The Revenue is expected to grow by 60.53% on average over the next years. This is a very strong growth
EPS Next Y17.67%
EPS Next 2Y-0.39%
EPS Next 3Y-8.95%
EPS Next 5Y1.3%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

VERU's earnings are expected to decrease with -8.95% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.39%
EPS Next 3Y-8.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERU INC

NASDAQ:VERU (4/30/2025, 8:00:01 PM)

Premarket: 0.56 +0.02 (+3.38%)

0.5417

-0.01 (-1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners35.42%
Inst Owner Change0.91%
Ins Owners10.62%
Ins Owner Change1.53%
Market Cap79.29M
Analysts81.82
Price Target2.81 (418.74%)
Short Float %12.56%
Short Ratio9.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.09%
Min EPS beat(2)-18.32%
Max EPS beat(2)20.51%
EPS beat(4)2
Avg EPS beat(4)-0.6%
Min EPS beat(4)-28.68%
Max EPS beat(4)24.1%
EPS beat(8)4
Avg EPS beat(8)3.01%
EPS beat(12)5
Avg EPS beat(12)-7.96%
EPS beat(16)8
Avg EPS beat(16)4.03%
Revenue beat(2)2
Avg Revenue beat(2)47.04%
Min Revenue beat(2)10.75%
Max Revenue beat(2)83.32%
Revenue beat(4)3
Avg Revenue beat(4)22.02%
Min Revenue beat(4)-41.15%
Max Revenue beat(4)83.32%
Revenue beat(8)4
Avg Revenue beat(8)1.72%
Revenue beat(12)6
Avg Revenue beat(12)-8.13%
Revenue beat(16)8
Avg Revenue beat(16)-3.95%
PT rev (1m)-14.06%
PT rev (3m)-19.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.33%
EPS NY rev (1m)0%
EPS NY rev (3m)21.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.91%
Revenue NY rev (1m)-14.21%
Revenue NY rev (3m)-56.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.7
P/FCF N/A
P/OCF N/A
P/B 2.45
P/tB 3.12
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.12
BVpS0.22
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.66%
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.02%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.62
Altman-Z -6.47
F-Score4
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y17.67%
EPS Next 2Y-0.39%
EPS Next 3Y-8.95%
EPS Next 5Y1.3%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%
EBIT growth 1Y61.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.36%
OCF growth 3YN/A
OCF growth 5YN/A